Morgan Stanley grew its holdings in Regenxbio Inc (NASDAQ:RGNX) by 217.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,959 shares of the biotechnology company’s stock after purchasing an additional 172,653 shares during the quarter. Morgan Stanley’s holdings in Regenxbio were worth $12,943,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of Regenxbio by 7.0% in the 2nd quarter. Bank of America Corp DE now owns 108,317 shares of the biotechnology company’s stock valued at $5,565,000 after purchasing an additional 7,126 shares during the period. Balyasny Asset Management LLC lifted its stake in shares of Regenxbio by 1,802.5% in the 2nd quarter. Balyasny Asset Management LLC now owns 152,521 shares of the biotechnology company’s stock valued at $7,835,000 after purchasing an additional 144,504 shares during the period. Vanguard Group Inc. lifted its stake in shares of Regenxbio by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 3,449,874 shares of the biotechnology company’s stock valued at $177,220,000 after purchasing an additional 44,452 shares during the period. Ellington Management Group LLC acquired a new position in shares of Regenxbio in the 2nd quarter valued at about $216,000. Finally, BlackRock Inc. lifted its stake in shares of Regenxbio by 3.5% in the 2nd quarter. BlackRock Inc. now owns 5,047,103 shares of the biotechnology company’s stock valued at $259,270,000 after purchasing an additional 169,888 shares during the period. 79.40% of the stock is currently owned by institutional investors.
RGNX stock opened at $39.50 on Friday. The stock’s 50 day simple moving average is $35.88 and its 200 day simple moving average is $45.29. Regenxbio Inc has a fifty-two week low of $30.38 and a fifty-two week high of $73.81. The company has a quick ratio of 14.58, a current ratio of 14.58 and a debt-to-equity ratio of 0.01.
A number of research firms recently weighed in on RGNX. Svb Leerink raised Regenxbio from an “underperform” rating to a “market perform” rating and dropped their price target for the stock from $38.00 to $37.00 in a research note on Tuesday, August 20th. Zacks Investment Research downgraded Regenxbio from a “hold” rating to a “sell” rating in a research note on Thursday, September 19th. ValuEngine raised Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. BidaskClub raised Regenxbio from a “sell” rating to a “hold” rating in a research note on Thursday, October 3rd. Finally, Morgan Stanley dropped their price target on Regenxbio from $85.00 to $59.00 and set an “overweight” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $76.78.
In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $49.49, for a total transaction of $742,350.00. Following the completion of the sale, the insider now directly owns 261,000 shares of the company’s stock, valued at approximately $12,916,890. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Patrick J. Christmas sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 19th. The stock was sold at an average price of $50.03, for a total value of $250,150.00. Following the sale, the senior vice president now directly owns 3,058 shares of the company’s stock, valued at $152,991.74. The disclosure for this sale can be found here. Insiders have sold a total of 50,486 shares of company stock valued at $2,183,662 over the last three months. Corporate insiders own 13.80% of the company’s stock.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
See Also: What is a Roth IRA?
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.